Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson's COVID vaccine is uniquely positioned to help end COVID around the globe. The network built to administer the vaccine globally will enhance the company's non-U.S. businesses significantly.

Silver Lining From Delta Variant Makes Johnson & Johnson More Attractive

CVS Health

CVS Health has stopped offering J&J's single-dose Covid-19 in its pharmacies but will continue to make the shots available at certain MinuteClinic locations.

CVS Health stops offering J&J Covid vaccine at its pharmacies, available at select MinuteClinics

Illumina

Moderna

Novartis

Regeneron Pharmaceuticals

Zoetis

Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.

Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN

Apple

Accenture Plc

Automatic Data Processing

CME Group

Costco

Cisco Systems

General Dynamics

Home Depot

Honeywell

Intel

Eli Lilly

Lockheed Martin

Mastercard

Medtronic

Merck

Microsoft

NIKE

PepsiCo

Procter & Gamble

Stryker

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

AstraZeneca

Pfizer

It'll push the winners further ahead of the laggards.

How the Delta Variant Could Change the World of Coronavirus Vaccine Stocks

On Friday, a jury in Illinois decided that Johnson & Johnson (NYSE: JNJ) was not liable for the death of 69-year-old Elizabeth Driscoll, who used the Company's talc-based powders for decades.  Driscoll's family had blamed Johnson & Johnson's products for causing her ovarian cancer.

Johnson & Johnson Cleared In Illinois Woman's Death In Talc Case, But Thousands Still Pending: Report

Johnson & Johnson (NYSE: JNJ) has withdrawn its application seeking accelerated approval of its COVID-19 vaccine, drugs regulator Drugs Controller General of India informed.  It is yet to be clear the reason for the withdrawal of the application.

Johnson & Johnson Pulls Application For Accelerated Approval Of COVID-19 Shot In India: Report

Catalyst Pharmaceuticals

They might not hit the moon, but there's a much smaller chance they'll bite the dust.

3 Top Robinhood Stocks to Buy in August Instead of Dogecoin

The healthcare giant has weathered much bigger storms in the past.

Will Johnson & Johnson Be Hurt by Its Sunscreen Product Recall?

A House Oversight subcommittee sent a letter to Johnson & Johnson's (NYSE: JNJ) CEO Alex Gorsky asking for documents and information on any company plans to place a subsidiary into bankruptcy over talc liabilities, Reuters reported. Democrat Raja Krishnamoorthi, chairman of the U.S. House of Representatives Committee on Oversight and Reform's subcommittee on economic and consumer policy, wrote that the panel is trying to learn how J&J's plans may affect people who have said the company's baby powder harmed them.

US House Panel Asks JNJ For Documents Over Talc Liabilities Bankruptcy Plan

WASHINGTON, July 29, 2021 /PRNewswire/ -- More than 30,000 women cancer victims would retain their constitutional right to have juries decide if talc in Johnson & Johnson's (NYSE:JNJ) baby products caused their ovarian cancer under bankruptcy reforms proposed Wednesday by key lawmakers in the U.S. Senate and House of Representatives. The Nondebtor Release Prohibition Act of 2021 would close controversial bankruptcy loopholes, including non-consensual third-party releases and the so-called "Texas Two-Step.

Women Cancer Victims Opposed to Johnson & Johnson's 'Texas Two-Step' Bankruptcy Ploy Urge Passage of Reforms Introduced by Warren, Durbin, Nadler, Blumenthal, and Maloney

Investors should consider more than just the healthcare giant's impressive financial numbers when deciding whether to invest in its stock over the long term.

Are Johnson & Johnson's Legal Troubles Enough of a Reason to Avoid the Stock?

Abbott Labs

Becton, Dickinson and Co.

You shouldn't invest your life savings into any one stock, but these three have some serious potential.

3 Dividend Stocks Safe Enough to Bet the Farm On

Shareholders bored by lagging returns might get some excitement in the near future.

Wall Street Might Be Missing This Key to Growth at Johnson & Johnson

The extension will give health workers six additional weeks to administer millions of doses of the single-shot vaccine.

FDA Extends Shelf Life Of Johnson & Johnson Covid-19 Vaccine To Six Months

A Black women's advocacy group filed a lawsuit Tuesday accusing Johnson & Johnson of selectively marketing the company's talcum-based products, including Johnson's Baby Powder, to African-American women despite knowing for years that the items had been linked to ovarian cancer, an allegation J&J denies.

Advocacy group sues Johnson & Johnson over cancer-linked powder products marketed to Black women

NEW BRUNSWICK, N.J., July 27, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Virtual Wells Fargo Healthcare Conference on Friday, September 10 th.

Johnson & Johnson to Participate in the Virtual Wells Fargo Healthcare Conference

In the face of a comprehensive global tax agreement intended to inhibit tax avoidance opportunities, industry executives and lobbyists are mounting a quiet campaign to push back against the measure, the Wall Street Journal reports.  This time, the pharma industry is using the goodwill garnered by the rapid deployment of COVID-19 vaccines as the new negotiating tool.

Pharma Heavyweights, Including Pfizer And JNJ Trying To Push Global Tax Deal Amid COVID-19 Role: WSJ

J & J Snack Foods

J&J Snack Foods Corp. (JJSF) CEO Daniel Fachner on Q3 2021 Results - Earnings Call Transcript

Intuitive Surgical

What healthcare executives are saying so far about the impact of the coronavirus variant on their businesses is reassuring.

Worries About the Delta Variant Could Be Overdone Based on Clues From These Healthcare Giants

The price action has tested resistance, while the option activity suggests that traders continue to both buy calls and sell puts.

News for Johnson & Johnson Stock (JNJ)